Antonio Giordano, Breast Medical Oncologist at Dana-Farber Cancer Institute, shared a post by DAVA Oncology on X, adding:
”A privilege to present the results of TRADE trial. Initial dose escalation strategy (50-100-150) for adjuvant abemaciclib allowed a greater number of patients to reach and maintain 150 mg BID dosing at 12-weeks than observed in monarchE.”
Quoting DAVA Oncology’s post:
”Dr. Antonio Giordan from Dana-Farber shares TRADE trial data: 70.8% of patients with early-stage HR+/HER2- BC reached and maintained 150mg BID abemaciclib at 12 weeks using a dose-escalation strategy. Toxicities were manageable, with low discontinuation for adverse events.”
More posts featuring Antonio Giordano.
